NEPC has poor prognosis with limited treatment options and a 5 year survival rate of < 20%11 and evolves via clonal evolution from adenocarcinomas in ~ 20% of CRPC cases12 via molecular events such as loss of tumor suppressors retinoblastoma (RB1) and tumor protein 53 (TP53). This evidence concerns the gene TP53 and adenocarcinoma.